$VBIO News
Last published 1d ago
- 1d agoVBIOValion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security ConferenceACCESS NewswireValion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today, on Veterans Day, announced that it will attend RW Baird's 2026 National Security Conference on November 17 in Washington, D.C. In conversations with defense stakeholders and institutional in ...
- 2w agoVBIOValion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety ResultsACCESS NewswireNIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome , after the announcement of positive safety findingsFully funded study will evaluate Entolimod's
- 2w agoVBIOValion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy EvaluationACCESS NewswireAFRRI study found no evidence of treatment-related toxicity following a single dose of Entolimod, supporting advancement toward a planned, fully funded therapeutic study evaluating survival and gastrointestinal recovery
- 2w agoVBIOValion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic OptionsACCESS NewswireUnsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod SAN ANTONIO, TX / ACCESS Newswire / October 26, 2026 / Valion Bio, Inc.
- 3w agoVBIOValion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder ValueACCESS NewswireInterim CEO Dean Zikria's initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company's integrated
- 4w agoVBIOValion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility MilestoneACCESS NewswireVelocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of
- 1mo agoVBIOWith Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO SurgeACCESS NewswireVelocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based production SAN
- 1mo agoVBIOValion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data CentersACCESS NewswireRising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors ¹Medical countermeasures need to scale along with that
- 1mo agoVBIONew Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of EntolimodACCESS NewswireJensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly
- 1mo agoVBIOValion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term OpportunityACCESS NewswireNeedle-free program creates a potential second development pathway alongside Valion's injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod into the
- 1mo agoVBIOValion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership TransitionsACCESS NewswireLeadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / Valion
- 1mo agoVBIOValion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing RuleACCESS NewswireNasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc.
- 2mo agoVBIOValion Bio Announces Changes to Management and Board of DirectorsACCESS NewswireCurrent CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.Lead Asset Positioned for Significant Markets: Entolimod
- 2mo agoVBIOValion Bio Announces Reverse Stock SplitACCESS NewswireSAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. announced today that its Board of Directors has declared a 1-for-25 reverse stock split of
- 3mo agoVBIOUkraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment PhaseACCESS NewswirePotential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry begins
- 3mo agoVBIOValion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI InjuryACCESS NewswireAFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early FallStudy drug delivered • IACUC approval secured • Safety study planned to start this
- 3mo agoVBIOUkraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence PathwayPR NewswireValion Bio, Inc. (Nasdaq: VBIO) today announced that Ukraine's Ministry of Health (MoH) has accepted the Company's regulatory dossier for Entolimod—a ...
- 3mo agoVBIOWorld-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia MarketPR NewswireValion Bio, Inc. (Nasdaq: VBIO) today announced a major clinical development milestone with the finalization of an clinical trial protocol at Sheba...
- 4mo agoVBIOValion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology ExpansionPR NewswireValion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the "Company") is pleased to report across a series of strategic initiatives for its Entolimod...
- 4mo agoVBIOAFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARSPR NewswireValion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the "Company") today announced that the Armed Forces Radiobiology Research Institute ("AFRRI"), a...
- 5mo agoVBIOValion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear CountermeasuresPR NewswireValion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the "Company") (f/k/a Tivic Health Systems, Inc.), a late-stage biopharmaceutical company, confirmed ...
- 5mo agoVBIOVALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROMEPR NewswireValion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation...
- 6mo agoVBIOValion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ PlatformPR NewswireValion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, today announced that its wholly...
- 6mo agoVBIOVALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSPR NewswireValion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, today reported financial results...
- 6mo agoVBIOValion Bio to Report First Quarter 2026 Financial Results on May 14, 2026PR NewswireValion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute...
- 6mo agoVBIOValion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™PR NewswireValion Bio, Inc. (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for acute radiation syndrome, oncology supportive...
- 6mo agoVBIOVALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSIONPR NewswireValion Bio, Inc. (Nasdaq: VBIO) (formerly Tivic Health Systems, Inc.), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute...
- 6mo agoVBIOTCRTValion Bio Appoints Melinda Lackey as General CounselPR NewswireValion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute...
- 6mo agoVBIOVALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROMEPR NewswireValion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a late-stage immunotherapeutics company, today announced that it briefed...
- 5y agoVBIOFDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 ProdrugGlobeNewswireCLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC:VBIO) ("Vitality" or the "Company"), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the U.S. F